The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats

Mareike S Pötsch, Anika Tschirner, Sandra Palus, Stephan von Haehling, Wolfram Doehner, John Beadle, Andrew Coats, Stefan D Anker, Jochen Springer

Research output: Contribution to journalArticlepeer-review

53 Citations (Scopus)


Sarcopenia, the age-related, progressive loss of skeletal muscle mass, strength, and function, is a considerable socioeconomic burden by increasing risks of falls, fractures, and frailty. Moreover, sarcopenic patients are often obese and therapeutic options are very limited.
Original languageEnglish
Pages (from-to)149-158
Number of pages10
JournalJournal of Cachexia, Sarcopenia and Muscle
Issue number2
Early online date22 Nov 2013
Publication statusPublished - Jun 2014

Cite this